Pfizer’s (NYSE:PFE) COVID-19 remedy Paxlovid was discovered to be ineffective in lessening the signs of lengthy COVID, based on a brand new examine.
Researchers at Stanford Drugs stated a 15-day routine of the drug, which is used to stop extreme COVID-19, didn’t reduce choose signs of lengthy COVID in 155 sufferers who had examined constructive for the SARS-CoV-2 virus.
Contributors had been contaminated with the virus for at the least 16 months, on common, earlier than enrolling within the examine. All had been experiencing moderate-to-severe instances of at the least two of six frequent COVID signs, together with shortness of breath, mind fog, fatigue and physique aches, based on Stanford Drugs.
Researchers stated that whereas Paxlovid didn’t seem to ease signs, the examine confirmed {that a} 15-day course of the drug was protected. The drug is generally given for less than 5 days.
Outcomes of the examine had been revealed within the June 7 problem of the Journal of the American Medical Affiliation’s Inner Drugs.
Stanford stated the examine was funded by Pfizer.